Network pharmacology study on the improvement of non-alcoholic fatty liver disease by using Cyperi Rhizoma after vinegar processed leading into liver
Article Sidebar
Main Article Content
Abstract
Aim to investigate the effect of vinegar processed Cyperus rotundus on enhancing the efficacy of drugs in the liver, this study used network pharmacology methods to explore the mechanism of vinegar processed Cyperus rotundus on improving non-alcoholic fatty liver disease (NAFLD). The author has compiled relevant literature from both domestic and international sources over the past 10 years, and based on the TCMSP database, identified 16 active ingredients and 471 related targets in vinegar processed Cyperus rotundus. Obtain 1,941 target genes for NAFLD using GeneCards, OMIM, and Drug Bank databases, among them, there are 104 common targets for drugs and diseases. Construct a "drug-ingredient-gene target" network and a PPI network using Cytoscape 3.10.0 software. Obtaining honeysuckle alcohol, isorhamnetin, kaempferol, and other active ingredients as the main active ingredients in the production of vinegar processed Cyperus rotundus in NAFLD. Importing potential targets into the String database for protein interaction analysis, constructing a protein-protein interaction (PPI) network, and identifying AKT1, JUN, IL6, IL1B, and other key target genes through analysis. Perform GO functional enrichment analysis and KEGG pathway analysis on the target of action, The enrichment results showed that vinegar processed Cyperus rotundus improved NAFLD and was associated with multiple liver related metabolic pathways, including TNF signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, and Toll-like receptor signaling pathway. The study shows that vinegar processed Cyperus rotundus may act on core targets such as AKT1, JUN, IL6, and IL1B through active ingredients such as honeysuckle alcohol, isorhamnetin and kaempferol, regulating signaling pathways such as TNF, MAPK, PI3K-Akt signaling to improve NAFLD.
Article Details
References
Li JX, Chen Q, Wang YL. Consensus opinion on integrated traditional Chinese and Western medicine diagnosis and treatment of non alcoholic fatty liver disease (2017). Chinese Journal of Integrated Traditional and Western Medicine on Digestion. 2017;25(11):805-11. (in Chinese)
Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease. Chinese Journal of Hepatology. 2006;14(3):161-3. (in Chinese)
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of liver diseases. Hepatology. 2018;67(1):328-57.
Younossi Z, Tacke F, Arrese M, Chander-Sharma B, Mostafa L, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-82.
Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. Guidelines for diagnosis and treatment of non alcoholic fatty liver disease. Journal of Practical Hepatology. 2007;(1):1-3.
Chinese Association of Traditional Chinese Medicine Spleen and Stomach Diseases Branch. Guidelines for traditional Chinese medicine diagnosis and treatment of non alcoholic fatty liver disease, grassroots doctor edition. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases. 2019;29(5):483-6. (in Chinese)
Wu DZ, Wang FQ (Editor). Modern famous traditional Chinese medicine treatment techniques for fatty liver. 2nd ed. Scientific and Technical Documentation Press; 2011. (in Chinese)
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (part 1). 11th ed. Beijing: China Medical Technology Press; 2020. (in Chinese)
Xu XM, Wang SQ. Application of Xiangfu in the treatment of coronary heart disease. Shanxi Journal of Traditional Chinese Medicine. 2012;28(10):41-2. (in Chinese)
Sheng FY, Zhou LJ, Yan X, Feng WW, Fu CM, Wang SX, et al. The effect of Xiangfu vinegar on liver Qi stagnation model rats before and after processing. Chinese Traditional Patent Medicine. 2016;38(1):156-9. (in Chinese)
Yang QH, Ling JS, Ping HH, Weng CY. Traditional Chinese medicine prevention and treatment strategies for nonalcoholic fatty liver. Journal of Traditional Chinese Medicine. 2007;48(8):746-8. (in Chinese)
Mu J, Wang QG, Wang XQ, Cheng FF, Wang ZS, Zhu WX, et al. On the mechanism of liver depression and phlegm production in non-alcoholic fatty liver disease. Global Traditional Chinese Medicine. 2017;10(1):34-6. (in Chinese)
Editorial Committee of Chinese Medicine Dictionary. Dictionary of traditional Chinese pharmacy. 2nd ed. Beijing: People's Health Publishing House; 2006. (in Chinese)
Ji NP. Basic research on the effective extracts from vinegar cooked Cyperus rotundus L. for the efficacy of resolving liver-Qi [dissertation]. Chengdu: Chengdu University of Traditional Chinese Medicine; 2015. (in Chinese)
Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chinese Journal of Natural Medicines. 2013;11(2):110-20.
Lu JR, Li WB, Wang SY, Fu CM, Zhou LJ, Yan X, et al. Contents comparison of cyperotundone, nootkatone and α-cyperone in Cyperi Rhizoma before and after vinegar processing. Chinese Journal of Experimental Traditional Medical Formulae. 2014;20(20):24-7. (in Chinese)
Zhou LK, Liu S, Wang Z, Yao JF, Cao WB, Chen SL, et al. Bone marrow-derived mesenchymal stem cells modified with Akt1 ameliorates acute liver GVHD. Biol Proced Online. 2019;21:24. (in Chinese)
Attanasio S, Ferriero R, Gernoux G, De Cegli R, Carissimo A, Nusco E, et al. CHOP and c-JUN up-regulate the mutant Z α1-antitrypsin, exacerbating its aggregation and liver proteotoxicity. J Biol Chem. 2020;295(38):13213-23.
Chen XR, Zhou YX, Xuan MX. Dynamic study of serum rrNF-d, IL-6 and IL-8 levels in patients with viral hepatitis. Chinese Journal of Infectious Diseases. 1999;17(2):115-7. (in Chinese)
Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol. 2011;55(5):1086-94.
Zhang Z, Guo M, Li Y, Shen M, Kong D, Shao J, et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy. 2020;16(8):1482-505.
Buitrago-Molina LE, Marhenke S, Becker D, Geffers R, Itzel T, Teufel A, et al. P53-in dependent induction of p21 fails to control regeneration and hepatocar cinogenesis in a murine liver injury model. Cell Mol Gastroenterol Hepatol. 2021;11(5): 1387-404.
López-Luque J, Caballero-Díaz D, Martinez-Palacián A, Roncero C, Moreno-Càceres J, García-Bravo M, et al. Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis. Hepatology (Baltimore, Md.). 2016;63(2):604-19.
Zhang C, Li CP. Current progress in mechanism of quercetin for treatment of non-alcoholic fatty liver disease. Traditional Chinese Drug Research and Clinical Pharmacology. 2015;26(5):718-21. (in Chinese)
Ying HZ, Liu YH, Yu B, Wang ZY, Zang JN, Yu CH. Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem Toxicol. 2013;52:53-60.
Vidyashankar S, Sandeep-Varma R, Patki PS. Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol In Vitro. 2013;27(2):945-53.
Zhou HY, Tang W, Jiang J, Song LH. Effect of β-sitosterol and stigmasterol on non-alcoholic fatty liver disease in vitro. Acta Nutrimenta Sinica. 2016;38(7):994-7. (in Chinese)
Wang X, Zhang L, Cai H, Bao B. Effect of luteolin on the alleviation of high fat diet induced non-alcoholic fatty liver disease in mice. Journal of Hefei University of Technology (Natural Science). 2016;39(7):994-7. (in Chinese)
Yang XJ. Effects of flavonoid from seed of Hippophae rhamnoides L. on lipid metabolism and its mechanism [dissertation]. Shanghai: East China Normal University; 2016. (in Chinese)
Zhao L, Yang L, Ahmad K. Kaempferol ameliorates palmitate-induced lipid accumulation in HepG2 cells through activation of the Nrf2 signaling pathway. Hum Exp Toxi col. 2023;42:9603271221146780.
You YH, Zhou MY, Hu JC, Zhu Z, Xu J. Research progress of kaempferol against liver diseases. China Medical Herald. 2024;21(6):58-61. (in Chinese)
Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, et al. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 2015;16(11):26087-124.
Venkatesan B, Valente AJ, Prabhu SD, Shanmugam P, Delafontaine P, Chandrasekar B. EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB and MKK7/JNK/AP-1 signaling. J Mol Cell Cardiol. 2010;49(4):655-63.
Han R, Zhang F, Wan C, Liu L, Zhong Q, Ding W. Effect of perfluorooctane sulphonate-induced Kupffer cell activation on hepatocyte proliferation through the NF-κB/TNF-α/IL-6-dependent pathway. Chemosphere. 2018;200:283-97.
Yang QY, Ma LL, Zhang C, Lin JZ, Han L, He YN, et al. Exploring the mechanism of indigo naturalis in the treatment of ulcerative colitis based on TLR4/MyD88/NF-κB signaling pathway and gut microbiota. Front Pharmacol. 2021;12:674416.
Sun J. Structural analysis of polysaccharides from Atractylodis Rhizoma and its protective mechanism on alcoholic bowel-liver tissue diseases [dissertation]. Changchun: Changchun University of Traditional Chinese Medicine; 2024. (in Chinese)
Sheng FY, Zhou LJ, Yan X, Feng WW, Fu CM, Wang SY, et al. Effects of Cyperus rotundus before and after vinegar processing on liver-Qi stagnation model rats. Chinese Traditional Patent Medicine. 2016;38(1):156-9. (in Chinese)
